Traduction de «drug development broadening access to medicines » (Néerlandais → Français) :

“This effort builds on the ongoing work of many partners committed to improving the lives of the 1 billion people affected by NTDs, most of whom are among the world’s poorest. “At Pfizer, we are working to combat NTDs by collaborating on drug development, broadening access to medicines and strengthening health care delivery for underserved people.
“At Pfizer, we are working to combat NTDs by collaborating on drug development, broadening access to medicines and strengthening health care delivery for underserved people.

Regulatory approvals, if achieved, would broaden access to affordable, highquality respiratory medicines and further reinforce Sandoz's position as a leader in differentiated generics.
Les autorisations réglementaires, si elles étaient obtenues, élargiraient l’accès à des médicaments respiratoires abordables et de grande qualité, en renforçant la position de Sandoz en tant que leader des génériques différenciés.

Delivering innovation, growth and productivity The success of Novartis is driven by a commitment to three strategic priorities: (1) extending our lead in innovation through the research and development of differentiated new medicines, vaccines and diagnostics; (2) accelerating growth across all divisions by broadening our product portfolios with new launches and increasing our presence in new markets; and (3) improving profitability through productivity by streamlining and simplifying our processes.
Promouvoir l'innovation, la croissance et la productivité Le succès de Novartis est porté par son engagement envers trois priorités stratégiques: Augmenter notre avance dans l’innovation en recherchant et développant de nouveaux médicaments, vaccins et diagnostics différenciés, 2) accélérer notre croissance dans toutes les divisions en élargissant notre portefeuille par le lancement de nouveaux de produits et en accroissant notre présence dans de nouveaux marchés et 3) améliorer notre profitabilité par le biais de la productivité en rationalisant et en simplifiant nos processus.

Allied and Complementary Medicine Koninklijk Besluit Association des Chiropracticiens Belges Belgian School of Osteopathy (Wet) Beroepen in de Individuele Gezondheidszorg Bristish Medical Association Belgisch Staatsblad Complementary and Alternative Medicine Collège Belge d’Ostéopathie Council of Chiropractic Education Comité Européen de Normalisation/ European committee for Standardization Cumulative Index of Nursing and Allied Health Literature Centre for Reviews and Dissemination Debategraph Doctor in chiropractic Diplomed in osteopathy (USA: Doctor in osteopathy) Evidence Based Medicine European Council on Chiropractic Education European School of Osteopathy Flanders International College of Osteopathy Fonds voor Wetenschappelijk Onderzoek Facilitated Positional Release Graduate Education Program Groupement National Représentatif des Professionnels de l’Ostéopathie/ Groepering, Nationaal en Representatief van de Professionele Osteopaten Grading of Recommendations Assessment, Development and Evaluation High Velocity Low Amplitude International Academy of Osteopathy Intervalle de confiance/betrouwbaarheidsintervallen International Chiropractors Association Institut William Gardner Sutherland Muscle Energy Techniques Mean Weighted Difference National Institute for Health and Clinical Excellence Nederlands Register voor Osteopathie Non Steroidal Anti-inflammatory Drug Organisation Mondiale de la Santé Wereldgezondheidsorganisatie World Health Organisation Beroepscompetentieprofiel Physiotherapy Evidence Database Proprioceptive Neuromuscular Facilitation
Association Belge des Ostéopathes Classique / Belgische Associatie van Klassieke Osteopaten America Chiropractic Association Anglo-European College of Chiropractic Allied and Complementary Medicine Arrêté Royal Association des Chiropracticiens Belges Belgian School of Osteopathy (Wet) Beroepen in de Individuele Gezondheidszorg Bristish Medical Association Complementary and Alternative Medicine Collège Belge d’Ostéopathie Council of Chiropractic Education Comité Européen de Normalisation European committee for Standardization Cumulative Index of Nursing and Allied Health Literature Centre for Reviews and Dissemination Debategraph Doctor in chiropractic Diplomed in osteopathy (USA: Doctor in osteopathy) Evidence Based Medicine European Council on Chiropractic Education European School of Osteopathy Flanders International College of Osteopathy Fonds National de le Recherche Scientifique Facilitated Positional Release Graduate Education Program Groupement National Représentatif des Professionnels de l’Ostéopathie/ Groepering, Nationaal en Representatief van de Professionele Osteopaten Grading of Recommendations Assessment, Development and Evaluation High Velocity Low Amplitude International Academy of Osteopathy Intervalle de confiance International Chiropractors Association Institut William Gardner Sutherland Moniteur Belge Muscle Energy Techniques Mean Weighted Difference National Institute for Health and Clinical Excellence Nederlands Register voor Osteopathie Non Steroidal Anti-inflammatory Drug Organisation Mondiale de la Santé Profil de compétences professionnel Physiotherapy Evidence Database Proprioceptive Neuromuscular Facilitation Randomised Controlled Trial Roland Morris Disability Questionnaire

How can we provide or improve access to our medicines, for people in both developing and developed nations?
Comment donner ou améliorer l’accès à nos médicaments, autant dans les pays développés qu’en voie de développement ?

This biotechnology drug represents an important advance in the development of personalized medicines since it specifically targets IL-1 beta, the major trigger of inflammation in auto-inflammatory diseases.
Ce médicament biotechnologique représente une avancée importante dans le développement de médicaments personnalisés, car il cible spécifiquement IL-1 bêta, le principal déclencheur de l’inflammation dans les maladies auto-inflammatoires.

Pharmaceuticals – Protez On June 4, Novartis agreed to acquire Protez Pharmaceuticals, a privately held US biopharmaceuticals company, gaining access to PTZ601, a broad-spectrum antibiotic in Phase II development against potentially fatal drug-resistant bacterial infections.
Pharmaceuticals – Protez Le 4 juin, Novartis a convenu d’acquérir Protez Pharmaceuticals, une société américaine de biotechnologie en mains privées. Cet accord a permis à Novartis d’accéder à PTZ-601, un antibiotique à large spectre en phase II de développement pour traiter des infections bactériennes potentiellement fatales qui résistent aux médicaments.